This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet Omnipod Insulin Pump Finds Favor in British Columbia
by Zacks Equity Research
Insulet's (PODD) Omnipod has huge market potential in Canada as it is the only tubeless insulin pump sold in the region.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
by Zacks Equity Research
Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.
MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE
by Zacks Equity Research
Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.
Walgreens (WBA) Tops Q3 Earnings Estimates, Narrows View
by Zacks Equity Research
Walgreens Boots (WBA) is upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U.S. pharmacies business.
Stryker (SYK) to Acquire SafeAir, Reduce Surgical Smoke
by Zacks Equity Research
The acquisition of SafeAir likely to boost Stryker's (SYK) core MedSurg and Neurotechnology segments.
Here's Why You Should Steer Clear of Fresenius Medical Now
by Zacks Equity Research
Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
ITGR vs. GMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
ISRG or ITGR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
Intuitive Surgical (ISRG) and Integer Holdings' (ITGR) strong fundamentals and rising share price make them close contenders.
3 Medical Instrument Stocks to Gain on Solid Market Prospects
by Zacks Equity Research
Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.
ITGR vs. GMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ITGR vs. GMED: Which Stock Is the Better Value Option?
Integer Holdings (ITGR) Up 18.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Integer Holdings (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Hits Fresh Highs: Is There Still Room to Run?
by Zacks Equity Research
Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.
Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.
Here's Why You Should Invest in Integer Holdings Right Now
by Zacks Equity Research
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Here's Why You Should Invest in Stryker (SYK) Right Now
by Zacks Equity Research
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Should Value Investors Pick Integer Holdings (ITGR) Stock?
by Zacks Equity Research
Is Integer Holdings (ITGR) a great pick from the value investor's perspective right now? Read on to know more.
Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.
Cardiovascular Systems' Micro Crown Now Available in Japan
by Zacks Equity Research
Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.
Abiomed Hits New 52-Week High: 3 Factors Driving the Stock
by Zacks Equity Research
Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.
Becton, Dickinson Completes Enrollment in Lutonix DCB Trial
by Zacks Equity Research
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.
Becton, Dickinson Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.
5 Reasons Why McKesson Deserves a Place in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.